Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07008118 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT07008118 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 120 participants, below the 137-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT07008118, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Conditions Studied
Interventions
- DRUG INCA035784
Study Locations (20)
Other
- Cliniques Universitaires Saint-Luc - Brussels
- Universitaire Ziekenhuizen Leuven - Leuven
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii - Mainz
- Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii - Bergamo
Texas
- South Austin Medical Center - Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood - Dallas
Arizona
- Mayo Clinic Hospital - Phoenix
California
- Stanford University - Palo Alto
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic-Florida - Jacksonville
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2029-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07008118
The ClinicalTrials.gov registry entry for NCT07008118 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (12% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which INCA035784 is the first listed.
NCT07008118 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT07008118 about?
NCT07008118 is a clinical study titled "A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms". This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
What is the current status of trial NCT07008118?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-10-01. Estimated completion is 2029-12-14.
What conditions does trial NCT07008118 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT07008118?
The interventions under investigation include: INCA035784 (DRUG).
Who is sponsoring clinical trial NCT07008118?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07008118 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
ACTIVE NOT RECRUITING · Phase 1
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.